ELRON - INVESTOR PRESENTATION March 2021 This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers, and nothing said therein constitutes a “public offering”, as defined in the Securities Law, 5728-1968. Elron may make improvements and/or changes in the features or content presented herein at any time. Elron shall not be liable for COMMENTS any loss, claim, liability or damage of any kind resulting from the investor's reliance on or reference to any detail, fact or opinion presented herein. The presentation is not intended to provide a comprehensive description of Elron's activities, and Elron urges investors to consider the information presented herein in conjunction with its public filings including its annual and other periodic reports. Nothing in this presentation should be considered "investment advice", as defined in the Israel Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 5755-1995. Certain statements made over the course of this presentation may be forward-looking in nature, as defined in Section 32A of the Israel Securities Law, 5728-1968. Such forward-looking statements involve known and unknown risks, uncertainties, forecasts, assessments, estimates or other information, which relates to a future event or matter whose occurrence is not certain and which is not within the sole control of Elron, and other factors which may cause the actual results, performance and achievements of Elron to be materially different from any future results, performance and achievements implied by such forward-looking statements. These forward looking statements are not proved facts and are based on Elron's subjective assessments which rely on analysis of general information, public publications, researches and reviews, which do not include any liability as to the accurateness or completeness of the information contained there and their accurateness hasn't been examined by Elron. The realization of these forward looking statements will be affected by factors that cannot be assessed in advance and which are not within the control of Elron. Elron assumes no obligation to update the information in this presentation and disclaims any obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. These estimates, in whole or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors that may affect this are developments in Elron’s and its group companies’ fields of operation; failure to meet goals; inability to realize technologies; modifications in technologies; modifications in work plan, goals and/or strategy; guidance and determinations by regulatory authorities; unforeseen regulatory difficulties; failure to obtain regulatory approvals; regulatory developments and changes in fields of operation; unforeseen developments in the course of clinical trials and trial results; reliance on third parties including data analysis services; feedback from the medical and scientific community; regulatory changes and restrictions on supply of raw materials for manufacture; inability to obtain financing; delays or malfunctions in development or manufacture; or if any risk associated with Elron and its group companies and the course of product development or sales occurs. In addition, the spread of the coronavirus (COVID-19) may lead to difficulties or delays in recruiting patients for clinical trials or initiating trial sites; operational constraints amassing raw material inventories; significant potential difficulties in raising capital for group companies; budget cuts among potential customers and subsequent decisions to increase product life-cycles rather than adopt new technology solutions; potential difficulties for group companies in closing commercial transactions or generating leads and managing lengthy and complex sale-cycles, among other things, due to mobility constraints between countries; a worldwide global slowdown that will make it difficult to execute exit transactions. In addition, as of the date of this presentation, the capital markets are experiencing high volatility, including significant stock price falls, due to the market response to the spread of the coronavirus (COVID-19). All amounts are fully attributed to Elron and RDC unless specified otherwise. 2 ELRON: WE SPECIALIZE IN Elron was established in 1962 by Uzia Galil

EARLY-STAGE INVESTMENTS WITH to bridge the gap between Israeli R&D SIGNIFICANT EXIT POTENTIAL and industry, and create “a knowledge- based industry” (later named hi-tech…) THE IDEA

We have close to 60 We rely on a We focus our years experience proven strategy investments in identifying of hands-on fields where we opportunities, involvement in bring added building technology the day-to-day value and are leaders, and exiting operations of our able to facilitate holdings group companies opportunities

3 BUILDING VALUE IN INVESTMENTS 1960s Defense Elbit 1970s Long-standing strategic 11 exits totaling $1.6b since Elscint 2010, including proceeds of partnership with Rafael, $590m for Elron and RDC providing our startups with tech 1980s assets & knowhow Semiconductors | Zoran 1990s Team of experienced VC Robust cyber / Communications professionals, field enterprise software Netvision | Partner experts & young portfolio 2000s innovators Multi-strategy 2010s Medical Devices 26 portfolio Medtech companies Medingo companies in which ripe for maturation (CartiHeal & BrainsGate) we invested ~$230m 2020s Cyber/Enterprise Software This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. Secdo 4 See Slide 2 of this presentation. TEAMWORK An experienced team which led 11 exits, dozens of investments, and follow-on financings totaling hundreds of millions of $s over the last decade

YARON ELAD NIV LEVY ZOHAR ROZENBERG ZVIKA SLOVIN CEO CFO Head of Cyber Head of Medtech Vast experience in tech Broad experience in Col. Ret. Headed the IDF’s Cyber Broad experience in the investing & strategic deals. accounting, financing, taxation, Division in the Intelligence Corp medical device space as an Established Elron’s software and securities regulations. 8200 unit. Established Elron’s entrepreneur and investor. activities. Led a string of M&A Oversees Elron’s financial cyber portfolio and successfully Was instrumental in the transactions over the last 14 operations, and plays a led the investment and sale of CartiHeal-Bioventus transaction years. Has been with Elron since significant role in the Secdo to Palo Alto Networks in and serves as CartiHeal’s 2007. company’s M&A and financing 2018 and Alcide to Rapid7 in chairman. Has been with Elron transactions. Has been with 2021. Has been with Elron since since 2008. Elron since 2009. 2016.

5 GROWING OUR CYBER / IT PORTFOLIO 2020 2021

Accelerate growth in Robust products with strong Exit Alcide acquired by Rapid7 mature companies market demand

3 major external uprounds OpenLegacy | IRONSCALES Boost value of 2nd Market validation set to in our mature companies | Sixgill generation companies drive near-term growth CYBER / IT PORTFOLIO Product-market fit Over $50m cash on hand nd SecuredTouch | ZenGo | Increase pace of new validation in our 2 for new and follow-on DEVELOPMENT Cynerio investments generation companies investments (following AND VALUE $16m injection into RDC PIPELINE Elron $8m | Rafael $8m) 3 new investments OneView | Imvision | Sightd

RIPENING THE VALUE OF OUR MEDICAL DEVICE COMPANIES 2020 2021 External Up Round | PMA submission | FDA Submit response to FDA feedback | Enhance feedback product for market readiness Deal with Bioventus for future acquisition upon FDA approval for up to $0.5b| FDA 'Breakthrough Final pivotal trial results Designation' | Submission of 1st PMA module

This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. 6 Our holdings based on 2021: YEAR OF Book value at Holdings in companies 1 valuation of last INVESTMENTS Dec. 31, 2020 ($m) financing round 2 ($m) Over $50m cash on hand (incl. RDC) for Medical: new and follow-on BrainsGate (25%) 1.1 40.7 investments CartiHeal (25%) 1.3 50.3 * Other medical companies 17.4 27.8 Total Medical Holdings 19.8 118.8 Total Cyber/Software Holdings 10.5 52.1 * Elron’s expected proceeds from the Others 3.9 3.8 Bioventus transaction if Total Holdings 34.2 174.7 the option to sell the Contingent consideration and proceeds in escrow 1.7 1.7 company is exercised from sale of companies amounts to $90m- Liquid resources (as of March 14, 2021) 36.5 36.5 $129m External debt - - TOTAL 72.4 212.9 Total – March 2020 182.8 Price per share on TASE (in $) (as of March 14, 2021) $3.65 Elron’s market value (as of March 14, 2021) 157.3

1 Includes Elron’s direct holdings and its effective indirect holdings through RDC. Includes investments made after Dec. 31, 2020. Includes Elron’s balance and 50.1% of RDC’s balance. 2 The amount includes: A) $147.9m calculated based on the “post-money” valuation of the last financing round in the companies multiplied by our fully diluted holding percentage. It is clarified that these are financing rounds that were carried out in different companies at different dates, and since which, in some cases, significant time has passed. In some of the financing rounds Elron and/or RDC opted not to participate; B) investments in companies presented at fair value in Elron’s financial statements totaling $17.8m (mainly Notal Vision and Aqwise); C) $9.0m attributed to Pocared based on a valuation determined with the assistance of an external appraiser as of Aug. 6, 2020 and which is included in Elron’s periodic report for Sept. 30, 2020. 3 The above financial data do not represent a valuation, investment advice, or a financial opinion of any kind. 7 Investing in Cybersecurity

Cybersecurity Cybersecurity M&As Funding

Time to exit $20b x4.9 $10.7b $2.7b in 109 rounds (4th highest all-time) 0-7 years 45.6% of companies (all-time high) (97% YOY) Total M&A Median exit Total VC investments Funding raised by Israeli co’s volume in 2020 multiple in 2020 0-10 years 59.8% of companies in 2020 in 2020

In 2020, there were 6 billion-dollar-plus M&A deals – a historical record, half of which were Israeli co’s: 5 Israeli- founded unicorns since 2019 acquires acquires acquires acquires acquires acquires

$2.8b $2.1b $1.6b $1.2b $1.1b $1b

Sources: Momentum Cyber: Cybersecurity Almanac | 2021, https://momentumcyber.com/docs/Yearly/2021_Cybersecurity_Almanac_Public_Edition.pdf; 8 https://www.techaviv.com/unicorns BUILDING VALUE CYBER & ENTERPRISE SOFTWARE IN VENTURE Value Creation CAPITAL INVESTMENTS

Building a seed portfolio

8 years 16 companies $134m value created 3.5 exits (2.8x multiple) $82m: our 17 external follow-on rounds $63m holdings based on last round invested in cyber & $52m: exit enterprise proceeds software companies

9 Exits include the secondary sale of a portion of our shares in IRONSCALES RDC: VALIDATION PLATFORM FOR DEEP-TECH ORIENTED INVESTMENTS IN EARLY STAGES

KOBI KATZ Chief Information Officer RDC: ELRON & RAFAEL’S JOINT INVESTMENT VENTURE RAFAEL FOR INITIATING & DEVELOPING NEW CO’s 25 years’ experience in system engineering, software Vast experience in technological projects; development and large-scale extensive knowledge in the cyber and enterprise technological management. Has been with RDC since 2013. software spaces

Well-established practice of serving as a design EXTENSIVE AD-HOC TEAMS partner / beta site for startups, and often as their ENGAGEMENT WITH FOR DEEP first major customer START-UPS AS PART TECHNOLOGICAL OF DUE DILIGENCE ASSESSMENT SUCCESSFUL CASE STUDIES: Secdo, Ironscales, Trapx, OzCode, Oneview, Cytegic, XMCyber, ASSISTANCE TO PORTFOLIO COMPANIES, Silverfort, Avecto, OPSWAT INCLUDING BY LEVERAGING ON RAFAEL'S CAPABILITIES

10 CYBER/ENTERPRISE SOFTWARE VALUE CREATION in $M

PROVEN CAPABILITIES EXIT IN BUILDING VALUE FROM SEED STAGE PARTIAL EXIT

EXIT EXIT

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

11 Exit

Exit

Exit

CYBER & ENTERPRISE SOFTWARE – GROWTH CATALYST IN THE NEXT DECADE

Seed Round A Round B Round C 12 Rapid7 is paying $50 million for Alcide, in which Elron Electronic Industries holds 24%.

TOP HEADLINES ON OUR CYBER/ ENTERPRISE SOFTWARE COMPANIES

13 OUR MATURE CYBER/ ENTERPRISE SOFTWARE COMPANIES OPENLEGACY

ESTABLISHED: 2013 FROM LEGACY SYSTEM TO APPLICATION IN RECORD SPEED

FIRST INVESTMENT: 2014 Key Clients Partners TOTAL INVESTMENT: $68M $8.2M OUR MAIN PARTNERS: INVESTMENT Commerzbank, OG Tech, SBI Group, Cardif, Silverhorn, Prytek, Leumi Partners

Raised $10m internal round, 23% followed by $20m strategic by RDC round led by SBI Holdings OpenLegacy automatically generates APIs directly from Total investment of $68m ($8m OUR legacy systems, proven to be 10X faster, with 75% TCO by us); $27m cash available for HOLDING reduction, thereby bypassing middleware / ESB solutions growth ($mn savings) Team of 110 employees, in 8 Significant YoY growth in 2020 NEXT STEPS: locations worldwide (US, Latin Growth through America, Hong Kong, Japan, channel sales & Europe, Israel) Proven land and expand business model; nearly zero churn new SaaS offering

This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. 15 IRONSCALES

ESTABLISHED: 2014

FIRST INVESTMENT: 2015

TOTAL INVESTMENT: $22.4M IRONSCALES 2020 milestones $1.4M MAIN PARTNERS: K1 Investment Management, THE BALANCE OF Garnered a Increased Surpassed 1,000 Jump Capital total of 7 ARR by customers OUR INVESTMENT awards in 72% worldwide

VISION: To protect enterprises from cyber phishing attacks

13% PRODUCT: Automated phishing IRONSCALES’ anti-phishing Raised $6m from Jump by RDC prevention, detection & platform uses AI and real-time Capital, a new investor, to response platform human intelligence to remove accelerate growth strategy OUR HOLDING malicious emails both before & We sold a portion of our 94% OF MALWARE IS after they land in the inbox DELIVERED VIA EMAIL holding through 2 Customers span the secondary sales for $5m An estimated $17,700 is lost technology, healthcare, financial while retaining a 13% every minute due to phishing services, retail & education holding, representing a 5x attacks industries, across the globe ROI Sources: CSO Online, March 9, 2020: Top cybersecurity facts, figures and statistics for 2020, https://www.csoonline.com/article/3153707/top-cybersecurity-facts- 16 figures-and-statistics.html SIXGILL

ESTABLISHED: 2014

FIRST INVESTMENT: 2016 2020 GROWTH

TOTAL INVESTMENT: $20.1M The number of The number of Between 2019 and clients doubled with employees MAIN PARTNERS: 2020 Sixgill doubled a focus on Global worldwide doubled $6M Sonae IM, REV Venture its YoY revenue 5000 clients, MSP & with presence in NA, OUR INVESTMENT Partners, OurCrowd, Terra law enforcement EMEA, APAC and Israel Venture Partners, Crowdstrike

Two major products VISION: To monitor & analyze Dark Sixgill projects similar were released, Web activity in order to provide growth for 2021 organizations with real time alerts & targeting MSP groups 23% actionable intelligence PRODUCT: Cyber intelligence OUR HOLDING platform that automatically & Positioned for growth and expansion covertly monitors the Dark Web Closed a $5.75m strategic partnership with Crowdstrike, The global threat intelligence including a 3-year license & OEM deal + $1m investment market is expected to grow to Raised $16m in a round led by Sonae IM and REV Venture Partners ~$20B in 2027, at a CAGR of 18% with participation by OurCrowd from 2020 to 2027

Sources: Verified Market Research, August 2020: "Threat Intelligence Market by Deployment Model (Cloud-Based, On-Premise), by Component (Solution, Service), by Organization Size (SMEs, Large Enterprises), by Vertical, Geography” 17 This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. OUR 2ND GENERATION CYBER/ ENTERPRISE SOFTWARE COMPANIES SECUREDTOUCH

ESTABLISHED: 2015

FIRST INVESTMENT: 2016 Market-product fit validated 2020 TOTAL INVESTMENT: $12.9M 4X increase in revenue

MAIN PARTNERS: Global Village $5M Advisory, Upwest Labs, Arvato OUR INVESTMENT Financial Solutions

VISION: To ensure early detection of account fraud, before a transaction takes place IMPROVE USER EXPERIENCE 28% PRODUCT: A mobile & browser by RDC SDK for online retailers and Intent Based Decisioning financial institutions to identify Analysis of more than 100 OUR HOLDING User + Device + Network anomalies indicating fraud different behavioral, device and network parameters identifies MARKET: The global fraud market “good” human behavior vs. REDUCE FRAUD estimated at $14B annually bots, scripted attacks and growing over 16% CAGR negative human intent

Sources: The global fraud detection and prevention market was valued at USD 13.59 billion in 2018 and is expected to reach USD 31.15 billion by 2024, 19 recording a CAGR of 16.42%: www.marketwatch.com. ZENGO

ESTABLISHED: 2018 Everything you need in a crypto wallet Faster setup, easier backups and recoveries, and FIRST INVESTMENT: 2018 unparalleled security

TOTAL INVESTMENT: $7.8M ZENGO 2020 HIGHLIGHTS MAIN PARTNERS: Benson Oak $1.3M Ventures, SamsungNEXT OUR INVESTMENT Acquired Product global launched for customers VISION: Make the global crypto the mass economy more accessible by providing market a crypto wallet that doesn’t compromise between security and 8% user experience PRODUCT: The first keyless crypto Gained Partnership traction OUR HOLDING wallet, that uses no private key or seed with VISA USA phrase, so only the customer controls their funds

MARKET: Global cryptocurrency market expected to reach ~$1.7B by 2027

Sources: Fortune Business Insights™, May 2020. Cryptocurrency Market to Reach USD 1,758.0 Million by 2027 20 VALUE-BUILDING EVENTS IN PIVOTAL COMPANIES CARTIHEAL

CARTILAGE & BONE REGENERATION IN JOINTS SUCH AS THE KNEE Cartilage injuries affect millions of patients worldwide. The need for a simple, fast, and off-the shelf solution to restore cartilage is an unmet challenge facing medicine today.

ESTABLISHED: 2009 $18.4M >500 patients were Stopped patient enrollment for FDA OUR treated to date with the pivotal clinical trial due to anticipated FIRST INVESTMENT: 2012 INVESTMENT implant in a series of success based on interim analysis; clinical trials Granted ‘Breakthrough Device Designation’ TOTAL INVESTMENT: $70M by the FDA; submitted 1st PMA module

MAIN PARTNERS: CE mark in hand with a NEXT STEPS: Complete patient follow-up Johnson & Johnson, broad indication allowing (end of 2021) for final analysis of the Accelmed, aMoon, 27% for sales in Europe trial’s results Bioventus

OUR HOLDING

3 weeks post-op 6 weeks post-op 12 months post-op

This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. 22 CartiHeal’s system is an investigational device in the U.S., not approved for marketing there. CARTIHEAL-BIOVENTUS TRANSACTION: HIGHLIGHTS

Announcement On July 16, 2020 Elron announced the signing of definitive agreements for an investment in CartiHeal and an option to acquire CartiHeal by Bioventus LLC for $350M-$500M

Transaction • A $15-20M investment in CartiHeal at a pre-money value of $180M, of which $15M was invested immediately • An exclusive call option for Bioventus to acquire 100% of CartiHeal’s share capital • A put option for CartiHeal to sell 100% of it share capital to Bioventus, exercisable upon FDA approval

Elron’s $126-129M in the aggregate, comprising of: Expected • $90-92M upon FDA approval • $36-37M at achievement of a sales milestone (at least $100M in revenues during a consecutive 12- Proceeds month period) The potential consideration represents a 5-7x multiple on Elron’s investment in CartiHeal Conditions Pivotal clinical trial success and FDA approval with a label consistent in all respects with pivotal clinical Precedent trial success Security • Sellers to Bioventus: A portion of the proceeds will be deposited in escrow to secure indemnification obligations of the sellers to Bioventus (Elron’s share: $12M) • Bioventus to CartiHeal: Payment of a $30M break-up fee to CartiHeal if Bioventus exercises its right to terminate the transaction within 30 days of receiving the pivotal clinical trial results • Bioventus to CartiHeal: Release of a $50M escrow deposit to CartiHeal and forfeiture of Bioventus’s shares in CartiHeal if Bioventus does not complete the acquisition following exercise of the call option or put option 23 This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. TIMELINE

Statistical report of Investment final trial results PMA by Bioventus Expected: End of submission $100M in 7/2020 2021 to FDA FDA approval revenues

Bioventus exercises break- CartiHeal CartiHeal up right Sellers CartiHeal Elron’s Sellers Elron’s $30M payment to share: share: CartiHeal PUT $90-92M $36-37M

30-day 45-day Payment of Payment of $15M 7.7% Notice decision decision proceeds proceeds

No break up Deposit $50M in Bioventus Bioventus escrow CALL Bioventus Bioventus 24 This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. ELECTRICAL STIMULATION-BASED TREATMENT FOR ISCHEMIC STROKE The annual number of new ischemic strokes in the USA is approximately 700,000. The ESTABLISHED: current treatment for stroke is very limited. 2000

$31M FIRST Clinical Studies: Over In Dec. 2020 the Based on the clinical OUR INVESTMENT: 1,400 patients in 4 company secured trial results, the INVESTMENT 2005 studies; clinical effects $14M at a pre-money company received the similar to Mechanical valuation of $147M, in CE Mark and submitted Thrombectomy but in a an investment round its FDA application TOTAL 24-hour window led by a new investor INVESTMENT: $111M NEXT STEPS: Submit response to FDA feedback and make product improvements for market readiness MAIN 28% PARTNERS: For its response letter to the FDA BrainsGate conducted ~40 tests (such as electromagnetic compatibility Johnson & (EMC), mechanical integrity, sterilization, biocompatibility) all of which passed except for one, which Johnson, needs to be repeated. BrainsGate is working to file the letter in H1/2021, which is due in Oct. 2021. OUR Medtronic, HOLDING tPA: MECHANICAL THROMBECTOMY: Boston clot-busting drug clot removal or aspiration with a catheter Scientific, Pitango, ~10% of stroke patients receive tPA ~7% of stroke patients undergo the procedure Cipio This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, Partners, 5728-1968. See Slide 2 of this presentation. BNP BrainsGate’s system is an investigational device in the U.S., not approved for marketing there. There is overlap between the usage of tPA and Mechanical Thrombectomy. 25 PIVOTAL CLINICAL TRIAL

May 24, 2019

“The cumulative evidence indicates that, for patients with confirmed cortical ischemia 8-24h after onset, SPG stimulation reduces post-stroke disability over the entire outcome range and increases the proportion of patients alive and independent 3 months after stroke.”

* BrainsGate estimates that ~25% of ischemic strokes are cortical. 26 EXITS AT A VALUE OF $1.6B Our share in proceeds $590M

Acquired by COVIDIEN

Sold to ROCHE

Sold to PALO ALTO Sold to Sold to NETWORKS ENABLENCE WAVE Sold to Sold to Sold to BRUKER Sold to SYSTEMS Sold to Sold to MICROSOFT ALVARION RAPID7 CORP VOLCANO ZOLL

May June Sept. Nov. Nov. Feb. Sept. Oct. July Apr. Feb. 2010 2010 2011 2011 2012 2014 2015 2015 2017 2018 2021

Including RDC 27 ~$283M SPECIALIZING IN EARLY-STAGE Total cash balance & investments INVESTMENTS in existing companies Led by a team with a proven value-creation track record; leveraging on Rafael’s tech capabilities

11 EXITS A ROBUST PORTFOLIO of cyber and SUMMARY in the last decade enterprise software companies

IN THE NEXT YEAR INVESTMENT OPPORTUNITY IN A Value-building events in PUBLIC COMPANY IN THE VC SPACE, pivotal companies PROVIDING THE WIDER PUBLIC WITH ACCESS TO PRIVATE START-UPS

This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. 28 THANK YOU. elron.com SIXGILL IRONSCALES SECUREDTOUCH

Cyber Automated Behavioral intelligence phishing biometrics- 23% 13% 28% platform that prevention, by RDC based user by RDC automatically & detection & The balance of our authentication covertly analyzes Our investment: response investment: for mobile apps Our investment: the dark web $6m platform $1.4m $5m OUR CYBERSECURITY CYNERIO SAYATA ZENGO COMPANIES Protecting the Automated, Crypto wallet connected 24% AI-based cyber that doesn’t 19% 8% medical device by RDC risk assessment by RDC compromise ecosystem solution for the between from cyber Our investment: insurance Our investment: security and Our investment: threats $3m industry $3.8m user experience $1.3m

KINDITE IMVISION SIGHTD

Encryption Automated, AI- Security platform that 28% based API security SAFE platform that 25% makes the cloud by RDC solution that by RDC detects and by RDC blind to data & detects security defeats SaaS- encryption keys Our investment: anomalies Our investment: native threats Our investment: $3.3m $2.0m $3.2m

30 OPENLEGACY OZCODE

Automated Debugging- OUR API as-a-Service integration 23% (DaaS) that 46% by RDC by RDC SOFTWARE platform that cuts COMPANIES speeds digital debugging transforma- Our investment: time to Our investment: tion $8.2m minutes $4.5m

ONEVIEW AUDIOBURST

AI-based AI-powered platform for audio search analyzing & 10% platform that 7% by RDC extracting discovers insights from content that satellite Our investment: is clickable to imagery $750K hear

31 NOTAL CARTIHEAL BRAINSGATE VISION

Implant for Electrical Remote cartilage and stimulation- monitoring of OUR bone 27% based 28% patients with 12% regeneration treatment age-related MEDICAL in load- for ischemic macular DEVICE bearing Our investment: stroke Our investment: degeneration Our investment: $13.9m COMPANIES joints $18.4m $31m

NITINOTES CORAMAZE POCARED

Minimally Transcatheter Rapid and invasive mitral valve automated 10% endoscopic 25% repair system 30% microbiology by Elron device for laboratory & RDC* treatment system of obesity Our investment: Our investment: Our investment: $3.0m €5.2m $87.4m

* Total economic rights by Elron & RDC: approximately 48% 32